That tops 14.8% on high-dose tirzepatide alone, though 27% dropped out over side effects. CNBC-TV18 says phase 3 is planned by end of 2026.
Recap by typeshit. Post by @cnbctv18india on Instagram.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
The OCTANE analysis of 194 Ro telehealth patients was presented at EASD 2026. It had no comparison group, and patients who stopped treatment were left out.
Industry estimates put a four-week supply near 150,000 won, below Mounjaro's 272,000 won, with launch possible before year-end pending approval.
Loading…